The stock of ARS Pharmaceuticals Inc (SPRY) has seen a 16.46% increase in the past week, with a 15.22% gain in the past month, and a 31.25% flourish in the past quarter. The volatility ratio for the week is 2.32%, and the volatility levels for the past 30 days are at 3.90% for SPRY.. The simple moving average for the past 20 days is 14.62% for SPRY’s stock, with a 28.50% simple moving average for the past 200 days.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
The stock has a 36-month beta value of 0.86. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 54.77M, and at present, short sellers hold a 31.29% of that float. On June 26, 2025, the average trading volume of SPRY was 1.50M shares.
SPRY) stock’s latest price update
The stock of ARS Pharmaceuticals Inc (NASDAQ: SPRY) has increased by 2.86 when compared to last closing price of 16.78.Despite this, the company has seen a gain of 16.46% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Scotiabank repeating the rating for SPRY by listing it as a “Sector Outperform.” The predicted price for SPRY in the upcoming period, according to Scotiabank is $30 based on the research report published on March 07, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $40. The rating they have provided for SPRY stocks is “Outperform” according to the report published on February 10th, 2025.
SPRY Trading at 19.31% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.75% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Karas Eric, who sale 15,000 shares at the price of $16.00 back on Jun 18 ’25. After this action, Karas Eric now owns 7,696 shares of ARS Pharmaceuticals Inc, valued at $240,000 using the latest closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.91 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -0.16. The total capital return value is set at -0.09. Equity return is now at value -6.91, with -5.64 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -280.6.
Currently, EBITDA for the company is -2.88 million with net debt to EBITDA at 1.47. When we switch over and look at the enterprise to sales, we see a ratio of 17.04. The receivables turnover for the company is 10.44for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.00.
Conclusion
To sum up, ARS Pharmaceuticals Inc (SPRY) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
